A systematic review of the international prevalence of BRCA mutation in breast cancer

Clinical Epidemiology
Nigel ArmstrongRuben Gw Quek

Abstract

A systematic review was conducted, summarizing international BRCA 1 or 2 (BRCA1/2) mutation prevalence in breast cancer. Databases (eg, Medline and Embase; N=7) and conferences were searched (January 2012 to December 2017). From 17,872 records, 70 studies were included. In 58 large (N>100) studies, BRCA1/2 mutation prevalence varied widely from 1.8% (Spain) in sporadic breast cancer to 36.9% (United States) in estrogen receptor/progesterone receptor low+ (1-9% on immunohistochemistry/human epidermal growth factor receptor 2-negative [HER2-]) breast cancer. In 2 large studies unselected for family history, ethnicity, sex, or age and no/unclear selection by breast cancer stage or hormone receptor (HR) status, germline BRCA (gBRCA) mutation prevalence was 2.9% (Italy) to 3.0% (South Korea). In the 4 large unselected triple-negative breast cancer studies, gBRCA mutation prevalence varied from 9.3% (Australia) to 15.4% (United States). gBRCA mutation prevalence in 1 large unselected HR positive/HER2- early breast cancer study was 5% (United States). In 2 large unselected metastatic breast cancer studies, gBRCA mutation prevalence was 2.7% (France) and 4.3% (Germany). Locally advanced breast cancer studies were small and not in unsel...Continue Reading

Citations

Apr 16, 2020·Cells·Elise BerthelNicole Dalla Venezia
Apr 22, 2020·Annual Review of Genomics and Human Genetics·Ranjit ManchandaEphrat Levy-Lahad
Jun 20, 2020·Nature Reviews. Clinical Oncology·Nora PashayanMartin Widschwendter
Apr 13, 2020·Breast Cancer Research and Treatment·Daniele GiardielloMarjanka K Schmidt
Oct 6, 2020·Frontiers in Cell and Developmental Biology·Maddison RoseEmma Bolderson
Feb 15, 2020·Human Genetics·Stephanie Boisson-Dupuis
Jul 19, 2020·Nature Communications·Tae-Min KimSangwoo Kim
Sep 20, 2020·BMC Cancer·Mann AngUNKNOWN South Australian Prostate Cancer Clinical Outcomes Collaborative (SA-PCCOC)
Feb 3, 2021·International Journal of Molecular Sciences·Arsen ArakelyanHans Binder
Feb 16, 2021·Current Breast Cancer Reports·Silvia J Serrano-GomezLaura Fejerman
Mar 13, 2021·Targeted Oncology·Laura CortesiChristian Jackisch
Mar 16, 2021·Breast Cancer : Basic and Clinical Research·Nabila El-SheikhMohamed Elrefaei
Feb 13, 2021·Veterinary and Comparative Oncology·Verônica Mollica GovoniBruno Cogliati
Mar 31, 2021·Clinical Breast Cancer·Reshma MahtaniUNKNOWN Breast Cancer Therapy Expert Group (BCTEG)
Apr 7, 2021·Der Pathologe·Hans H Kreipe, P Sinn
May 26, 2021·Cell Stress & Chaperones·Armando Aranda-Anzaldo, Myrna A R Dent
Jun 5, 2021·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Karen A GelmonUNKNOWN Collaborating Investigators
Jul 25, 2021·Cancers·Fernando Augusto Batista CamposElizabeth Santana Dos Santos
Oct 14, 2021·Statistical Methods in Medical Research·Lauren J BeesleyJeremy Mg Taylor

❮ Previous
Next ❯

Software Mentioned

Excel

Related Concepts

Related Feeds

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.